L
Lyfegen
A value-based healthcare agreements platform for Healthcare Payers, Healthcare Providers, Pharma and MedTech
About Lyfegen
Lyfegen is a Swiss health-tech company that has developed a platform to help healthcare payers, pharmaceutical companies, and medical device manufacturers manage value-based agreements. The company's software enables these organizations to create and scale agreements where the price of a drug or treatment is based on the patient's outcome. This approach, known as value-based healthcare, aims to shift the focus from the volume of services provided to the quality of care and patient results.
The Lyfegen platform facilitates the collection and analysis of real-world data to measure patient outcomes and determine the effectiveness of treatments. This data-driven approach allows for more transparent and fair pricing of innovative and often expensive therapies. The platform also automates the administrative processes associated with these complex contracts, reducing the burden on healthcare staff and improving efficiency.
Lyfegen's business model is based on a subscription fee for its software-as-a-service (SaaS) platform. The company targets a global market, with a focus on regions that are increasingly adopting value-based healthcare models. By providing a neutral and trusted platform, Lyfegen aims to foster collaboration between stakeholders in the healthcare ecosystem and accelerate the adoption of value-based pricing for medical technologies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Basel, Switzerland
- Employees
- 65
- Open positions
- 5
- Dealroom signal
- 89.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, AI Drug Discovery, Techbio, Hard Tech, Techbio Drug Discovery, Digital Pharma, slush24, slush23, DT and LS
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2024 | $5.7M | $40M | aMoon Fund · TX Ventures | ↗ |
| GRANTOther financing | May 2023 | $0 | — | Innosuisse | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Lyfegen is 4.7K monthly website visits, up 176.5% over the last three months. Lyfegen's team grew 16.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Innosuisse
Series A3 investors entered at this stage
aMoon Fund
APEX Ventures
TX Ventures
Other known investors4 additional known investors
Swissnex
MassChallenge
Plug and Play
Startup Creasphere
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lyfegen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lyfegen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.